These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 11758578)

  • 1. The Hatch-Waxman Act during patent prosecution and beyond.
    Mahn TG
    Food Drug Law J; 1999; 54(2):233-6. PubMed ID: 11758578
    [No Abstract]   [Full Text] [Related]  

  • 2. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA's role in administering the Hatch-Waxman Act.
    Malkin BJ
    Food Drug Law J; 1999; 54(2):211-4. PubMed ID: 11758575
    [No Abstract]   [Full Text] [Related]  

  • 4. Overview of the Hatch-Waxman Act and its impact on the drug development process.
    Mossinghoff GJ
    Food Drug Law J; 1999; 54(2):187-94. PubMed ID: 11758572
    [No Abstract]   [Full Text] [Related]  

  • 5. Patenting drug products: anticipating Hatch-Waxman issues during the claims drafting process.
    Mahn TG
    Food Drug Law J; 1999; 54(2):245-53. PubMed ID: 11758582
    [No Abstract]   [Full Text] [Related]  

  • 6. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
    Kelly C
    Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H
    Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
    [No Abstract]   [Full Text] [Related]  

  • 8. A new history and discussion of 180-day exclusivity.
    Korn DE; Lietzan E; Scott SW
    Food Drug Law J; 2009; 64(2):335-90. PubMed ID: 19999288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA
    J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
    [No Abstract]   [Full Text] [Related]  

  • 10. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract]   [Full Text] [Related]  

  • 11. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
    Rea TS
    Food Drug Law J; 1999; 54(2):223-5. PubMed ID: 11759713
    [No Abstract]   [Full Text] [Related]  

  • 12. 2004 update--180-day exclusivity under the Hatch-Waxman amendments to the federal Food, Drug, and Cosmetic Act.
    Lietzan EK
    Food Drug Law J; 2004; 59(4):459-63. PubMed ID: 15875350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug costs threaten patent protection.
    Cimons M
    Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
    [No Abstract]   [Full Text] [Related]  

  • 15. Navigating the Hatch-Waxman Act's safe harbor.
    Jones PB
    Food Drug Law J; 2002; 57(3):475-89. PubMed ID: 12710407
    [No Abstract]   [Full Text] [Related]  

  • 16. The biotechnology industry organization's view on Hatch-Waxman reform.
    Schmickel D
    Food Drug Law J; 1999; 54(2):241-2. PubMed ID: 11758580
    [No Abstract]   [Full Text] [Related]  

  • 17. Use patents, carve-outs, and incentives--a new battle in the drug-patent wars.
    Rai A
    N Engl J Med; 2012 Aug; 367(6):491-3. PubMed ID: 22873529
    [No Abstract]   [Full Text] [Related]  

  • 18. The History and Political Economy of the Hatch-Waxman Amendments.
    Lietzan E
    Seton Hall Law Rev; 2019; 49(1):53-127. PubMed ID: 30557922
    [No Abstract]   [Full Text] [Related]  

  • 19. Protecting the balance of Hatch-Waxman: understanding the industry's new dynamics for the 21st century.
    Schroeder RG; Papas P
    Food Drug Law J; 2001; 56(1):19-26. PubMed ID: 11942348
    [No Abstract]   [Full Text] [Related]  

  • 20. Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.
    Grabowski HG; Kyle M; Mortimer R; Long G; Kirson N
    Health Aff (Millwood); 2011 Nov; 30(11):2157-66. PubMed ID: 22068409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.